Tetsuji Naka

17.1k total citations · 4 hit papers
202 papers, 13.4k citations indexed

About

Tetsuji Naka is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Tetsuji Naka has authored 202 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 62 papers in Immunology and 60 papers in Molecular Biology. Recurrent topics in Tetsuji Naka's work include Cytokine Signaling Pathways and Interactions (51 papers), Clusterin in disease pathology (18 papers) and Immune Cell Function and Interaction (15 papers). Tetsuji Naka is often cited by papers focused on Cytokine Signaling Pathways and Interactions (51 papers), Clusterin in disease pathology (18 papers) and Immune Cell Function and Interaction (15 papers). Tetsuji Naka collaborates with scholars based in Japan, United States and Australia. Tetsuji Naka's co-authors include Tadamitsu Kishimoto, Minoru Fujimoto, Akihiko Yoshimura, Masato Kubo, Satoshi Serada, Akihiro Kimura, Norihiro Nishimoto, Masashi Narazaki, Shizuo Akira and Tomoshige Matsumoto and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Tetsuji Naka

196 papers receiving 13.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SOCS proteins, cytokine signalling and immune regulation

2007 1.3k citations Tetsuji Naka et al. profile →
Structure and function of a new STAT-induced STAT inhibitor

1997 1.1k citations Tetsuji Naka, Tadamitsu Kishimoto et al. profile →
The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation

1994 908 citations Tetsuji Naka, Tadamitsu Kishimoto et al. profile →
SOCS-1 Participates in Negative Regulation of LPS Responses

2002 552 citations Tetsuji Naka, Minoru Fujimoto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tetsuji Naka Japan	54	6.4k	5.1k	3.7k	1.5k	1.4k	202	13.4k
Matthias Ernst Australia	68	5.6k 0.9×	5.7k 1.1×	5.6k 1.5×	2.0k 1.3×	1.2k 0.9×	220	15.2k
Fred Schaper Germany	40	4.3k 0.7×	5.0k 1.0×	3.3k 0.9×	1.2k 0.8×	1.0k 0.8×	96	9.9k
Valeria Poli Italy	66	5.0k 0.8×	5.1k 1.0×	6.1k 1.7×	2.1k 1.4×	2.4k 1.8×	148	16.0k
Christian Schindler United States	46	5.9k 0.9×	5.1k 1.0×	3.5k 0.9×	1.3k 0.9×	1.3k 1.0×	82	10.7k
Massimo Gadina United States	55	6.4k 1.0×	4.1k 0.8×	3.5k 1.0×	794 0.5×	1.1k 0.8×	126	13.2k
Lionel Feigenbaum United States	61	9.0k 1.4×	4.3k 0.8×	4.5k 1.2×	879 0.6×	1.2k 0.9×	123	15.1k
Iris Behrmann Germany	46	4.4k 0.7×	5.0k 1.0×	5.9k 1.6×	1.9k 1.3×	1000 0.7×	92	11.6k
Yuka Kanno United States	59	11.4k 1.8×	3.9k 0.8×	4.3k 1.2×	1.2k 0.8×	1.1k 0.8×	97	17.3k
Arian Laurence United States	50	10.1k 1.6×	3.9k 0.8×	2.7k 0.7×	811 0.5×	1.2k 0.9×	98	15.0k
Brendan J. Jenkins Australia	43	3.8k 0.6×	4.0k 0.8×	2.8k 0.8×	1.2k 0.8×	644 0.5×	113	8.6k

Countries citing papers authored by Tetsuji Naka

Since Specialization

Citations

This map shows the geographic impact of Tetsuji Naka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tetsuji Naka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tetsuji Naka more than expected).

Fields of papers citing papers by Tetsuji Naka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tetsuji Naka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tetsuji Naka. The network helps show where Tetsuji Naka may publish in the future.

Co-authorship network of co-authors of Tetsuji Naka

This figure shows the co-authorship network connecting the top 25 collaborators of Tetsuji Naka. A scholar is included among the top collaborators of Tetsuji Naka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tetsuji Naka. Tetsuji Naka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ikenaga, Naoki, Tsuyoshi Takahashi, Koji Tanaka, et al.. (2025). Overexpression of Transferrin Receptor in Esophageal Squamous Cell Cancer Suggests Poor Prognosis and Potential Therapy. Cancer Science. 117(2). 393–406.

Takahashi, Tsuyoshi, Koji Tanaka, Kazuyoshi Yamamoto, et al.. (2024). Lipolysis-stimulated lipoprotein receptor promote lipid uptake and fatty acid oxidation in gastric cancer. Gastric Cancer. 27(6). 1258–1272. 5 indexed citations

Serada, Satoshi, Minoru Fujimoto, Tomoharu Ohkawara, et al.. (2021). Gene therapy with SOCS1 induces potent preclinical antitumor activities in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine. 51(2). 126–133. 6 indexed citations

Nakajima, Hideki, Kimiko Nakajima, Mikiro Takaishi, et al.. (2021). The Skin–Liver Axis Modulates the Psoriasiform Phenotype and Involves Leucine-Rich α-2 Glycoprotein. The Journal of Immunology. 206(7). 1469–1477. 8 indexed citations

Matsuzaki, Shinya, Satoshi Serada, Koji Matsuo, et al.. (2021). CD70 antibody‐drug conjugate: A potential novel therapeutic agent for ovarian cancer. Cancer Science. 112(9). 3655–3668. 13 indexed citations

Serada, Satoshi, Tsuyoshi Takahashi, Takashi Matsunaga, et al.. (2021). Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma. Molecular Cancer Therapeutics. 20(9). 1713–1722. 15 indexed citations

Kato, Daiki, Tomonori Yaguchi, Takashi Iwata, et al.. (2020). GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. eLife. 9. 47 indexed citations

Kitagawa, Koichi, Yuka Fukui, Hiroki Saito, et al.. (2019). Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo. Cancer Gene Therapy. 26(11-12). 388–399. 16 indexed citations

Serada, Satoshi, et al.. (2019). Myosin heavy chain, a novel allergen for fish allergy in patients with atopic dermatitis. British Journal of Dermatology. 181(6). 1322–1324. 5 indexed citations

10.

Nakagawa, Satoshi, Satoshi Serada, Kosuke Hiramatsu, et al.. (2018). Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell–Mediated Antitumor Immunity By Suppressing PD-L1. Molecular Cancer Therapeutics. 17(9). 1941–1950. 8 indexed citations

11.

Sugase, Takahito, Tsuyoshi Takahashi, Satoshi Serada, et al.. (2017). SOCS1 Gene Therapy Improves Radiosensitivity and Enhances Irradiation-Induced DNA Damage in Esophageal Squamous Cell Carcinoma. Cancer Research. 77(24). 6975–6986. 37 indexed citations

12.

Hiramatsu, Kosuke, Satoshi Serada, Takayuki Enomoto, et al.. (2017). LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake. Cancer Research. 78(2). 516–527. 33 indexed citations

13.

Shinzaki, Shinichiro, Hideki Iijima, Hironobu Fujii, et al.. (2017). A novel pathogenesis of inflammatory bowel disease from the perspective of glyco-immunology. The Journal of Biochemistry. 161(5). 409–415. 7 indexed citations

14.

Umegaki‐Arao, Noriko, Katsuto Tamai, Keisuke Nimura, et al.. (2013). Karyopherin Alpha2 Is Essential for rRNA Transcription and Protein Synthesis in Proliferative Keratinocytes. PLoS ONE. 8(10). e76416–e76416. 9 indexed citations

15.

Ishii, Hiroshi, Shihori Tanabe, Masaki Ueno, et al.. (2013). ifn-γ-dependent secretion of IL-10 from Th1 cells and microglia/macrophages contributes to functional recovery after spinal cord injury. Cell Death and Disease. 4(7). e710–e710. 55 indexed citations

16.

Shinzaki, Shinichiro, Hideki Iijima, Hironobu Fujii, et al.. (2012). Lectin-based Immunoassay for Aberrant IgG Glycosylation as the Biomarker for Crohnʼs Disease. Inflammatory Bowel Diseases. 19(2). 321–331. 36 indexed citations

17.

Ohguro, Nobuyuki, Kei Nakai, Fumitaka Terabe, et al.. (2010). Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Experimental Eye Research. 91(2). 162–170. 82 indexed citations

18.

Terabe, Fumitaka, Minoru Fujimoto, Satoshi Serada, et al.. (2010). Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis. Inflammatory Bowel Diseases. 17(2). 491–502. 14 indexed citations

19.

Kimura, Akihiro, Tetsuji Naka, Keiko Nohara, Yoshiaki Fujii‐Kuriyama, & Tadamitsu Kishimoto. (2008). Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proceedings of the National Academy of Sciences. 105(28). 9721–9726. 429 indexed citations

20.

Hirano, Tôru, Shinji Higa, Junsuke Arimitsu, et al.. (2005). Luteolin, a flavonoid, inhibits AP-1 activation by basophils. Biochemical and Biophysical Research Communications. 340(1). 1–7. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact